SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-061080
Filing Date
2023-11-08
Accepted
2023-11-08 16:05:27
Documents
65
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fate-20230930.htm   iXBRL 10-Q 2969168
2 EX-4.3 fate-ex4_3.htm EX-4.3 34447
3 EX-31.1 fate-ex31_1.htm EX-31.1 13338
4 EX-31.2 fate-ex31_2.htm EX-31.2 13457
5 EX-32.1 fate-ex32_1.htm EX-32.1 9307
  Complete submission text file 0000950170-23-061080.txt   12768949

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fate-20230930_pre.xml EX-101.PRE 378513
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fate-20230930_lab.xml EX-101.LAB 493473
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fate-20230930_def.xml EX-101.DEF 251348
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fate-20230930_cal.xml EX-101.CAL 45558
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fate-20230930.xsd EX-101.SCH 60995
59 EXTRACTED XBRL INSTANCE DOCUMENT fate-20230930_htm.xml XML 3236880
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 231387759
SIC: 2836 Biological Products, (No Diagnostic Substances)